SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
BIONEX the Holy Grail for blood treatment (v.aaf)
An SI Board Since October 2001
Posts SubjectMarks Bans Symbol
1 0 0 AAF
Emcee:  thesurvivor Type:  Moderated
Introduction Market Data Compact
The BIONEX compound "The Holy Grail for Blood Treatment"

Discussions about the blood contamination around the world and what methods are used to prevent the transmission of deadly diseases.

Many conventional methods have been used to date to clean the blood supply. But is it enough?

There is a new compound called the BIONEX. Altachem Pharma Ltd owns the world wide rights to its patents and is working on its research, its development and its distribution on the market.

The potential market for blood treatment is over 10 billion dollars a year that is the estimate from CERUS corporation that has a possible compound still in research (NASDAQ: CERS).

Other related websites:

altachempharma.com

stockhouse.com

Subject 36747

Subject 36755
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1Dude, you're a one trick pony.Glenn Petersen-10/24/2001
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2024 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News